NCT07637851
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07637851
Title Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer (RegeNovar)
Acronym RegeNovar
Recruitment Not yet recruiting
Gender female
Phase Phase Ib/II
Variant Requirements No
Sponsors ARCAGY/ GINECO GROUP
Indications
Therapies
Age Groups: senior | adult
Covered Countries FRA


No variant requirements are available.